AMPH Amphastar P

This article provides a comprehensive analysis of Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH), highlighting a mid-channel oscillation pattern and a significant risk-reward short setup. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report suggests that while short-term and mid-term signals are neutral, a long-term weak bias may be easing.

Rice Hall James & Associates LLC recently acquired a new position in Amphastar Pharmaceuticals, Inc., purchasing 129,339 shares valued at approximately $3.45 million, representing 0.28% ownership. This move comes as other institutional investors have also adjusted their holdings in the company. Analysts currently rate Amphastar as a "Hold" with an average target price of $31.00, while recent insider transactions show sales of approximately 35,808 shares.

Amphastar Pharmaceuticals recently received FDA approval for its teriparatide injection prefilled pen, coinciding with a director's stock sale following option exercise. This approval is seen as a helpful, but not transformational, catalyst for the company's growth, which also operates an ongoing share repurchase program. Investors are weighing the potential benefits of the new product against recent profit margin compression and earnings declines.

Squarepoint Ops LLC significantly reduced its stake in Amphastar Pharmaceuticals by 67% in Q2, selling 46,744 shares. Despite this, Amphastar exceeded quarterly earnings expectations, and analysts maintain a consensus "Hold" rating with an average target price of $31.00. Insider selling has also been noted, with 35,808 shares sold in the last 90 days, though insiders still collectively own 27.5% of the company's stock.

Amphastar Pharmaceuticals (AMPH) has seen its share price stabilize and bounce about 3% over the past week and 5% over the past month, despite being down sharply year-to-date. Analysts have a consensus price target of $32.0, suggesting the stock may be undervalued at its current trading price of $27.32. The article indicates that while the stock has pulled back, its modest growth and potential for higher margins from its expanding U.S. manufacturing and proprietary pipeline could present an opportunity.

Amphastar Pharmaceuticals (AMPH) has seen a recent rebound, with its stock up 5.3% in the last week, even after significant year-to-date and annual declines. Despite volatility from pipeline updates and regulatory developments, the company scores as undervalued on valuation checks. Both Discounted Cash Flow and Price-to-Earnings analyses suggest the stock is significantly undervalued, presenting a potential opportunity for investors in 2025.